Published: November 2023
On 20 November 2023, IASO Biotechnology made a notable entrance at the 6th China International Import Expo (CIIE) by introducing FUCASO, the world's first fully human CAR-T therapy. This groundbreaking treatment has forged strategic alliances with several global medical institutions, instilling hope for a cure among multiple myeloma (MM) patients on a global scale. FUCASO has demonstrated remarkable efficacy, prompting lasting and profound remissions with a favorable safety profile in patients facing r/rMM and having exhausted multiple therapy options. Its distinctive design enables prolonged persistence within patients, addressing the persistent challenge of relapsed MM.
Within just four months of securing approval for market distribution in China, FUCASO has garnered attention from patients spanning various countries, drawing them to seek treatment within Chinese medical facilities. These hospitals boast world-leading expertise in the comprehensive management of CAR-T therapy. Furthermore, the cost of FUCASO treatment in China is notably lower compared to similar products available in Europe and America, thereby extending its benefits to a larger global patient base.
According to Roots Analysis, CAR T cell therapy market size is poised to reach USD 25 billion by 2035, growing at a CAGR of 20% from 2022 to 2035.
For detailed insights about this domain, check out our report on CAR T cell therapy market or email firstname.lastname@example.org
You may also be interested in the following titles:
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry
SUBSCRIBE TO INDUSTRY UPDATES